Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TACR3 | P29371 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498214 | 0.84 | PDE10A (0.62) | LMNATACR3TSHRPDE10ADHODH | |
| SCHEMBL9502807 | 0.82 | DHODH (0.64) | LMNATACR3TSHRPDE10ADHODH | |
| SCHEMBL523879 | 0.79 | ADORA3 (0.48) | SMN1; SMN2LMNAMEN1KMT2AADORA3 | |
| SCHEMBL620989 | 0.79 | ADORA3 (0.60) | SMN1; SMN2LMNAMEN1KMT2AADORA3 | |
| SCHEMBL27583476 | 0.78 | PDE10A (0.60) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL11065774 | 0.77 | LMNA (0.48) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL9505833 | 0.74 | DHODH (0.50) | LMNAMAPTTACR3TSHRPDE10A | |
| SCHEMBL8069465 | 0.74 | SCN9A (0.81) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3906503 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAMEN1KMT2AADORA3 | |
| SCHEMBL9501944 | 0.73 | DHODH (0.59) | LMNATACR3TSHRPDE10ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017676-B1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060189809-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-08-24 | — | — | US | claimed |
| US-20050171152-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-08-04 | — | — | US | claimed |
| US-20040049031-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1017676-A4 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020173657-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | claimed |
| US-20020038029-A1 | Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | SMITHKLINE BEECHAM CORPORATION | 2002-03-28 | — | — | US | claimed |
| US-6335448-B1 | NK-3 RECEPTOR ANTAGONISTS ARE USEFUL IN TREATING THE SYMPTOMS OF COPD AND URINARY INCONTINENCE IN MAMMALS. | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | claimed |
| EP-1017676-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999014196-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-25 | — | — | WO | claimed |
| EP-1017676-B1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1017676-B1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060189809-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-08-24 | — | — | US | disclosed |
| EP-1652840-A2 | (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050171152-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20020173657-A1 | Method for the synthesis of quinoline derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020038029-A1 | Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | SMITHKLINE BEECHAM CORPORATION | 2002-03-28 | — | — | US | disclosed |
| US-6335448-B1 | NK-3 RECEPTOR ANTAGONISTS ARE USEFUL IN TREATING THE SYMPTOMS OF COPD AND URINARY INCONTINENCE IN MAMMALS. | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | disclosed |
| EP-1017676-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014196-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189809-A1 | Method for the synthesis of quinoline derivatives | NQO2, CYP3A4, NQO1 | SMN1; SMN2 3701/4885LMNA 1556/4885MEN1 2226/4885 |
| US-20020038029-A1 | Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | RPP30, HPD, HRH4 | SMN1; SMN2 4166/4885LMNA 4118/4885MEN1 3213/4885 |
| US-20020173657-A1 | Method for the synthesis of quinoline derivatives | NQO2, QARS1, QPCT | SMN1; SMN2 3654/4885LMNA 1996/4885MEN1 2060/4885 |
| US-20050171152-A1 | Method for the synthesis of quinoline derivatives | NQO2, QARS1, QPCT | SMN1; SMN2 3623/4885LMNA 1697/4885MEN1 1860/4885 |
| US-20040049031-A1 | Method for the synthesis of quinoline derivatives | NQO2, NQO1, CYP3A4 | SMN1; SMN2 3684/4885LMNA 1836/4885MEN1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.